Min D, Kim D, Hong S, Kim J, Kim M, Kwon S
Sci Rep. 2025; 15(1):5148.
PMID: 39934167
PMC: 11814099.
DOI: 10.1038/s41598-025-89127-5.
Nehme J, Maassen S, Bravaccini S, Zanoni M, Gianni C, De Giorgi U
EMBO J. 2025; .
PMID: 39930269
DOI: 10.1038/s44318-025-00371-x.
Zhou C, Zhao L, Zhou M, Wu C, Liu G, Long J
Cancer Cell Int. 2024; 24(1):430.
PMID: 39726048
PMC: 11674180.
DOI: 10.1186/s12935-024-03626-5.
Sun R, Li S, Ye W, Lu Y
Cancer Cell Int. 2024; 24(1):419.
PMID: 39702158
PMC: 11661007.
DOI: 10.1186/s12935-024-03586-w.
Jeyapriya M, Kumar S, Nirmal M
Cureus. 2024; 16(9):e69790.
PMID: 39429383
PMC: 11491047.
DOI: 10.7759/cureus.69790.
Peptide-coated DNA nanostructures as a platform for control of lysosomal function in cells.
Elblova P, Lunova M, Henry S, Tu X, Cale A, Dejneka A
Chem Eng J. 2024; 498.
PMID: 39372137
PMC: 11448966.
DOI: 10.1016/j.cej.2024.155633.
Characterization of prognostic signature related with twelve types of programmed cell death in lung squamous cell carcinoma.
Li S, Ding B, Weng D
J Cardiothorac Surg. 2024; 19(1):569.
PMID: 39354528
PMC: 11443789.
DOI: 10.1186/s13019-024-03039-5.
UNC13B regulates the sensitivity of Wilms' tumor cells to doxorubicin by modulating lysosomes.
Chen X, Bao Y, Sun G, Wang X, Zhu J
Oncol Lett. 2024; 28(3):446.
PMID: 39091580
PMC: 11292464.
DOI: 10.3892/ol.2024.14579.
Challenges of Regulated Cell Death: Implications for Therapy Resistance in Cancer.
DAmico M, De Amicis F
Cells. 2024; 13(13.
PMID: 38994937
PMC: 11240625.
DOI: 10.3390/cells13131083.
Acidic sphingomyelinase interactions with lysosomal membranes and cation amphiphilic drugs: A molecular dynamics investigation.
Scrima S, Lambrughi M, Favaro L, Maeda K, Jaattela M, Papaleo E
Comput Struct Biotechnol J. 2024; 23:2516-2533.
PMID: 38974886
PMC: 11226985.
DOI: 10.1016/j.csbj.2024.05.049.
Lysosomal cation channel TRPML1 suppression sensitizes acute myeloid leukemia cells to chemotherapeutics by inhibiting autophagy.
Dai M, Lin B, Li H, Wang Y, Wu M, Wei Y
Mol Cell Biochem. 2024; 480(2):1209-1224.
PMID: 38951379
DOI: 10.1007/s11010-024-05054-5.
Interactions between genistein and Wnt pathway in colon adenocarcinoma and early embryos.
Azbazdar Y, Sosa E, Monka J, Kurmangaliyev Y, Tejeda-Munoz N
Heliyon. 2024; 10(11):e32243.
PMID: 38947477
PMC: 11214441.
DOI: 10.1016/j.heliyon.2024.e32243.
Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy.
Wan P, Zhong L, Yu L, Shen C, Shao X, Chen S
Front Immunol. 2024; 15:1384633.
PMID: 38799454
PMC: 11117069.
DOI: 10.3389/fimmu.2024.1384633.
Lysosomes in Cancer-At the Crossroad of Good and Evil.
Eriksson I, Ollinger K
Cells. 2024; 13(5.
PMID: 38474423
PMC: 10930463.
DOI: 10.3390/cells13050459.
Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.
Shirbhate E, Singh V, Mishra A, Jahoriya V, Veerasamy R, Tiwari A
Mini Rev Med Chem. 2024; 24(15):1449-1468.
PMID: 38343053
DOI: 10.2174/0113895575287242240129120002.
Activation of invasion by oncogenic reprogramming of cholesterol metabolism via increased NPC1 expression and macropinocytosis.
Skorda A, Lauridsen A, Wu C, Huang J, Mrackova M, Winther N
Oncogene. 2023; 42(33):2495-2506.
PMID: 37420029
PMC: 10421736.
DOI: 10.1038/s41388-023-02771-x.
Machine learning-based prognostic modeling of lysosome-related genes for predicting prognosis and immune status of patients with hepatocellular carcinoma.
Li W, Wang Q, Lu J, Zhao B, Geng Y, Wu X
Front Immunol. 2023; 14:1169256.
PMID: 37275878
PMC: 10237352.
DOI: 10.3389/fimmu.2023.1169256.
A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas.
Di Filippo L, de Carvalho S, Duarte J, Luiz M, Dutra J, de Paula G
Mater Today Bio. 2023; 20:100671.
PMID: 37273792
PMC: 10238751.
DOI: 10.1016/j.mtbio.2023.100671.
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
Villarruel-Melquiades F, Mendoza-Garrido M, Garcia-Cuellar C, Sanchez-Perez Y, Perez-Carreon J, Camacho J
World J Gastroenterol. 2023; 29(17):2571-2599.
PMID: 37213397
PMC: 10198058.
DOI: 10.3748/wjg.v29.i17.2571.
The Combination Sorafenib-raloxifene-loratadine as a Novel Potential Therapeutic Approach Against Human Liver Cancer.
Villarruel-Melquiades F, Hernandez-Gallegos E, Solano-Agama C, Mendoza-Garrido M, Camacho J
In Vivo. 2023; 37(3):1156-1163.
PMID: 37103074
PMC: 10188024.
DOI: 10.21873/invivo.13190.